Study of Immune Responses to Influenza Vaccination

Influenza Vaccination Clinical Trial

Official title:

Study of Immune Responses to Influenza Vaccination

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03346772
• Other study ID #: 820590
• Status: Recruiting
• Phase: Phase 4
• Start date: October 20, 2017
• Est. completion date: July 1, 2024

Study information

• Verified date: October 2023
• Source: University of Pennsylvania
• Contact: Sokratis Apostolidis, MD
• Phone: 267-584-6653
• Email: sokratis.apostolidis[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Better understanding of the immune responses to influenza vaccination is needed in order to understand situations of poor vaccine response. Adults will receive influenza vaccination and then have peripheral blood drawn at pre-defined intervals in order to study the lymphocyte responses.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 75
• Est. completion date: July 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Community-dwelling adults able to provide consent who need influenza vaccination for standard of care

Exclusion Criteria:

• febrile illness at time of vaccination
• active malignancy
• use of immunosuppressing medications
• blood donation in the past 60 days
• influenza vaccinated during the preceding 6 months
• allergic reactions to influenza vaccination

Related Conditions & MeSH terms

• Influenza Vaccination
• Influenza, Human

Intervention

Biological:
• Influenza vaccination
Adults will receive one intramuscular dose of seasonal quadrivalent inactivated influenza vaccine, as indicated for standard of care.

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Influenza neutralizing antibody titers		21-42 days